Top Tweets for #LiquidBX

about 1 year ago

@ElizSMcKenna #newPI from @NIH to start the Cancer Prevention & Tumor Evolution lab @Nemours! We are interested in discovering & validating #biomarkers in cancer predispositions (#EndNF) as well as using #liquidbx in clinical & preclinical models of #childhoodcancer for adaptive risk modeling

0

7

1

2

632

about 1 year ago

The @NIH has been amazing for me, but I’m excited for the next chapter: https://t.co/T64p5J215m R. Taylor Sundby: Excited to Open the Doors to My Own Lab at Nemours Children’s Hospital/Thomas Jefferson Medical School - OncoDaily #newPI #endNF1 #supportgold #liquidbx

0

12

0

1

209

Aadel Chaudhuri, MD PhD @aadel_chaudhuri

over 1 year ago

#ASCO25 @ASCO #EarlyDetection #CancerScreening #LiquidBx Abs 100: Reflex blood-based methylated ctDNA multi-cancer early detection (MCED) test in people with obesity: • 🔬 Overall sensitivity for correct tissue of origin (TOO): ~30% • 🎯 High specificity: 99% & NPV 98.9% • 💥 Promising PPV for obesity-related cancers: - Hepatobiliary 100% - Colorectal 87.5% - Upper GI 81.8% - Uterine 66.7% - Pancreaticobiliary 17.6% • 🩺 Detects early stage cancers with meaningful sensitivity This innovative test fills a critical screening gap for obesity-associated cancers. Prospective validation ongoing.

0

2

1

447

over 1 year ago

This is huge!!! Generous support from @ChildrensTumor and @curenfwithjack as we begin to move our NF1 #liquidbx #cfdna assay from research to the clinic. @MayoRadOnc @MayoCancerCare @MayoClinic @MayoClinicPath @WashUOncology @washumedicine @NIHClinicalCntr @NIH @theNCI

over 1 year ago

Grateful to @ChildrensTumor and @curenfwithjack's generous support of our (@MayoClinic-@NIHClinicalCntr -@washumedicine) efforts to move our NF1 #liquidbx #cfdna assay from research to the clinic! Read more: https://t.co/1xmixGi3jw @jack_shern @aadel_chaudhuri @AngelaHirbe

1

20

3

1

3K

1

22

4

0

2K

Pangea Biomed @PangeaBiomed

over 1 year ago

Grateful to @ChildrensTumor and @curenfwithjack's generous support of our (@MayoClinic-@NIHClinicalCntr -@washumedicine) efforts to move our NF1 #liquidbx #cfdna assay from research to the clinic! Read more: https://t.co/1xmixGi3jw @jack_shern @aadel_chaudhuri @AngelaHirbe

1

20

3

1

3K

Tuvik Beker @BekerTuvik

about 2 years ago

To beat cancer, we must all join forces! Very proud to be part of the #LiquidBX consortium, working with other innovative companies and research labs to push the boundaries of liquid biopsy technologies. Kudos to @ILInnovationAut for providing the funding to realize this vision.

about 2 years ago

We’re advancing cancer care in the next phase of the #LiquidBX consortium. With funding from @ILInnovationAut, we're developing biomarkers for treatment response, leveraging omics data from over 1,000 solid cancer cases. Details in WebWire: https://t.co/n4rHmUStMG

0

2

1

0

124

0

2

0

75

Pangea Biomed @PangeaBiomed

about 2 years ago

We’re advancing cancer care in the next phase of the #LiquidBX consortium. With funding from @ILInnovationAut, we're developing biomarkers for treatment response, leveraging omics data from over 1,000 solid cancer cases. Details in WebWire: https://t.co/n4rHmUStMG

0

2

1

0

124

about 2 years ago

19/ In summary, our #liquidbx methods pioneer a platform to both (1) improve outcomes and (2) decentralize aspects of prevention. This would ⬇️ the burden of care in cancer predispositions that, like NF1, require lifelong surveillance.

1

4

0

55

about 2 years ago

1/ Can #liquidbx detect pre-malignancy & guide intervention to avert cancer before it develops? Our recent @NCIResearchCtr -@MayoClinic-@washumedicine led collaboration’s @CCR_AACR publication (https://t.co/M8zW6EOQbg) suggests that it can in #neurofibromatosis (NF1). A 🧵:

3

27

7

4

3K

Neurofibromatosis Therapeutic Acceleration Program @ntapresearch

about 2 years ago

It was a huge privilege to co-lead the #liquidbx team with @PughLab. There are immense scientific + clinical opportunities w/ motivated multi-disciplinary teams working on them. I have no doubt that huge strides will be made in #NF1 care through #collaboration & #openscience!

about 2 years ago

The #NF1 Nerve Sheath Tumor Biomarker Development Symposium brought together creative thinkers and powerful do-ers to identify the most promising liquid, tissue, imaging and digital records markers to inform therapeutics for #NF1 tumors. Learn more: https://t.co/hYyWLapW3Z

ntapresearch's tweet photo. The #NF1 Nerve Sheath Tumor Biomarker Development Symposium brought together creative thinkers and powerful do-ers to identify the most promising liquid, tissue, imaging and digital records markers to inform therapeutics for #NF1 tumors.

Learn more: https://t.co/hYyWLapW3Z https://t.co/htgQv54Icj

0

10

3

0

2K

0

17

1

614

about 2 years ago

And, of course, a very special thanks to @ChildrensTumor for supporting the circulating proteomic #liquidbx part of the story! Great colleagues and allies towards the common goal to #endNF

0

8

0

141

Aadel Chaudhuri, MD PhD @aadel_chaudhuri

over 2 years ago

A star studded #liquidbx conference organized by @PughLab, @aadel_chaudhuri, @BrunaPellini, @NCIResearchCtr’s Adam Sowalsky/Sean Agbor-Enoch and others! Excited & intimated to present early #NF1 circulating #proteomic data tomorrow @ 11!

over 2 years ago

@NIH liquid biopsy conference in Bethesda starting off strong with keynote address by the one & only Dennis Lo!

0

9

2

0

1K

1

6

0

304

over 2 years ago

In @ASCO’s Daily News our @NCI_CCR_PedOnc-@WUSTLmed -@MayoClinic #collaboration discuss the transformative potential for #cfDNA #liquidbx in hereditary cancer syndrome surveillance. We highlight strives by @landau_lab, @PughLab and others towards this 🥅 https://t.co/PWzgObMnlW

1

20

6

0

4K

over 2 years ago · Thessalonica

Thrilled to be invited to speak at the 7th Hellenic Conference of Oncology @myESMO. Looking forward to a great meeting with @g_mountzios, @marilykmd and many more. @GreekOncol #LiquidBx @isliquidbiopsy

CharuAggarwalMD's tweet photo. Thrilled to be invited to speak at the 7th Hellenic Conference of Oncology @myESMO. Looking forward to a great meeting with @g_mountzios, @marilykmd and many more.
@GreekOncol #LiquidBx @isliquidbiopsy https://t.co/Uf9RTNVByN

1

35

2

0

2K

Christian Rolfo @ChristianRolfo

over 3 years ago · Chicago

#ASCO23 #LiquidBx

over 3 years ago

ctDNA Tumor Fraction continue to accumulate data as biomarker. The safir 2 study from @BenjaminBesseMD and group shown this in Durvalumab, with survival outcomes. #liquidbiopsy @isliquidbiopsy #ASCO23

ChristianRolfo's tweet photo. ctDNA Tumor Fraction continue to accumulate data as biomarker. The safir 2 study from @BenjaminBesseMD and group shown this in Durvalumab, with survival outcomes. #liquidbiopsy @isliquidbiopsy #ASCO23 https://t.co/QheyJfr1g6

0

24

8

4

6K

0

3

2

0

729

over 3 years ago

#ASCO23 @ASCO Integrating #LiquidBx Into Patient Care and Clinical Trial Design Mon, Jun 5, 445CDT https://t.co/LHzgeyl4Y8 @lillian_siu @geoff_oxnard @ChristianRolfo @drgandara

CharuAggarwalMD's tweet photo. #ASCO23 @ASCO

Integrating #LiquidBx Into Patient Care and Clinical Trial Design

Mon, Jun 5, 445CDT

https://t.co/LHzgeyl4Y8

@lillian_siu @geoff_oxnard @ChristianRolfo @drgandara https://t.co/MuaoDlAYHI

0

35

11

2

5K

over 3 years ago

#ASCO23 Abs#9076 Utility of ctDNA TF in case of negative LBx rin #NSCLC Important implications for use of ctDNA: Elevated TF (≥1%) = High NPV Negative LBx with low TF ( < 1%) should reflex to TBx #LiquidBx @ChristianRolfo @geoff_oxnard @Oncoalert @ASCO @HemOncToday @ASCOPost

0

14

7

1

2K

over 3 years ago · Baltimore

MPNST #sarcoma is the #1 cause of mortality in #NF1. Early detection and accurate dx of pre-malignant atypical NF is critical to improve outcome. Excited that our @WUSTLmed @NCI_CCR_PedOnc #liquidbx collaboration will have two platform talks @ChildrensTumor mtg re: early dx

1

11

3

0

893